Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress

Reasearch, , ,

Johnson & Johnson (NYSE: JNJ) announced today that 11 oral presentations from the Company’s industry-leading solid tumor portfolio and pipeline will be featured at the 2024 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) 2024 Congress. Twenty-seven studies (23 company-sponsored and four investigator-initiated), including four late-breaking abstracts, will feature new data in lung, bladder, prostate, and colorectal cancers. Continue reading

Related posts:

  1. New Research in JNCCN Highlights the Negative Impact of Continued Exclusion of Racial Groups from Research on Cancer Genomics
  2. PROSTATE CANCER FOUNDATION-FUNDED GENETIC STUDY OF MEN OF AFRICAN ANCESTRY FINDS NEW RISK FACTORS FOR PROSTATE CANCER
  3. FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies
  4. Vegetarians more likely to be depressed than meat-eaters – possible reasons